BridgeBio Pharma shares jump as investors focus on fresh BBP-418 data at MDA meeting and near-term regulatory milestones

BridgeBio Pharma, Inc. (BBIO) is up 13.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to renewed optimism around BBP-418 ahead of and during the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 8–11, 2026), where BridgeBio scheduled multiple presentations. This could also reflect investors positioning around the company’s stated intent to pursue an FDA NDA timeline for BBP-418 and continued early commercial traction for Attruby.

Details:

BridgeBio said additional interim Phase 3 FORTIFY data for BBP-418 in LGMD2I/R9 would be presented at the 2026 MDA Clinical & Scientific Conference, including a late-breaking oral session and multiple posters across March 10–11.

The MDA conference agenda includes an industry forum breakfast presented by BridgeBio on Tuesday, March 10, which may have concentrated investor attention on the program that day.

In its Q4/FY2025 update, BridgeBio highlighted positive interim Phase 3 FORTIFY results and indicated an intent to submit a BBP-418 NDA in the first half of 2026 (with additional regulatory work underway outside the U.S.).

BridgeBio also scheduled a March 10 fireside chat at a healthcare investor conference, which can act as a sentiment catalyst when management reiterates milestones and commercial commentary.

Sources:

BridgeBio Pharma Investor Relations, U.S. SEC, Muscular Dystrophy Association

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BBIO Insider Trading Activity

$BBIO insiders have traded $BBIO stock on the open market 86 times in the past 6 months. Of those trades, 0 have been purchases and 86 have been sales.

Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:

NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 62 sales selling 484,220 shares for an estimated $33,031,706.
FRANK MCCORMICK has made 0 purchases and 6 sales selling 200,000 shares for an estimated $13,313,192.
ANDREW LO has made 0 purchases and 4 sales selling 95,599 shares for an estimated $6,319,662.
ANDREA ELLIS sold 64,921 shares for an estimated $4,211,301
RONALD J DANIELS sold 61,031 shares for an estimated $3,888,999
THOMAS TRIMARCHI (President and CFO) has made 0 purchases and 4 sales selling 30,534 shares for an estimated $2,141,551.
HANNAH VALANTINE sold 25,484 shares for an estimated $1,683,727
RANDAL W. SCOTT has made 0 purchases and 5 sales selling 20,000 shares for an estimated $1,421,021.
MARICEL APULI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 2,510 shares for an estimated $186,418.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$BBIO Hedge Fund Activity

We have seen 242 institutional investors add shares of $BBIO stock to their portfolio, and 222 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PRICE T ROWE ASSOCIATES INC /MD/ added 2,261,181 shares (+144.2%) to their portfolio in Q4 2025, for an estimated $172,957,734
JANUS HENDERSON GROUP PLC added 2,259,378 shares (+25.8%) to their portfolio in Q4 2025, for an estimated $172,819,823
MACQUARIE GROUP LTD removed 1,933,096 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $147,862,513
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,602,036 shares (-78.0%) from their portfolio in Q4 2025, for an estimated $122,539,733
VIKING GLOBAL INVESTORS LP removed 1,583,915 shares (-9.9%) from their portfolio in Q4 2025, for an estimated $121,153,658
WELLINGTON MANAGEMENT GROUP LLP added 1,329,537 shares (+130.4%) to their portfolio in Q4 2025, for an estimated $101,696,285
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,051,679 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $80,442,926

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$BBIO Congressional Stock Trading

Members of Congress have traded $BBIO stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 09/22.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$BBIO Analyst Ratings

Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Barclays issued a "Overweight" rating on 01/28/2026
Truist Securities issued a "Buy" rating on 01/08/2026
Morgan Stanley issued a "Overweight" rating on 01/06/2026
JP Morgan issued a "Overweight" rating on 11/07/2025
HC Wainwright & Co. issued a "Buy" rating on 11/03/2025
Goldman Sachs issued a "Buy" rating on 10/31/2025
Cantor Fitzgerald issued a "Overweight" rating on 10/30/2025

To track analyst ratings and price targets for $BBIO, check out Quiver Quantitative's $BBIO forecast page.

$BBIO Price Targets

Multiple analysts have issued price targets for $BBIO recently. We have seen 16 analysts offer price targets for $BBIO in the last 6 months, with a median target of $95.0.

Here are some recent targets:

Trevor Allred from Oppenheimer set a target price of $81.0 on 02/25/2026
Danielle Brill from Truist Securities set a target price of $95.0 on 02/25/2026
Sean Laaman from Morgan Stanley set a target price of $98.0 on 02/25/2026
Cory Kasimov from Evercore ISI Group set a target price of $125.0 on 02/25/2026
Raghuram Selvaraju from HC Wainwright & Co. set a target price of $100.0 on 02/17/2026
Derek Archila from Wells Fargo set a target price of $98.0 on 02/13/2026
Eliana Merle from Barclays set a target price of $80.0 on 01/28/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.